Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month Low - Time to Sell?

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) reached a new 52-week low on Thursday . The stock traded as low as $9.51 and last traded at $9.54, with a volume of 247828 shares. The stock had previously closed at $9.71.

Analyst Ratings Changes

Several equities analysts have recently issued reports on NTLA shares. Wells Fargo & Company decreased their price target on Intellia Therapeutics from $70.00 to $60.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. Barclays lowered their target price on Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating for the company in a research note on Friday, November 8th. Canaccord Genuity Group restated a "buy" rating and issued a $90.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Chardan Capital lifted their price target on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a "buy" rating in a report on Monday, November 18th. Finally, Oppenheimer dropped their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a research note on Monday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $51.06.

Intellia Therapeutics Stock Up 0.8 %

The company has a market cap of $967.58 million, a price-to-earnings ratio of -1.75 and a beta of 1.83. The firm has a 50 day moving average price of $13.30 and a two-hundred day moving average price of $18.62.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. The business's revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.38) EPS. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -5.11 earnings per share for the current year.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 28,735 shares of company stock valued at $349,909 over the last quarter. Insiders own 3.20% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NTLA. ARK Investment Management LLC increased its holdings in Intellia Therapeutics by 5.7% in the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company's stock worth $251,849,000 after purchasing an additional 659,651 shares in the last quarter. State Street Corp grew its position in shares of Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after buying an additional 780,754 shares during the period. Geode Capital Management LLC increased its stake in shares of Intellia Therapeutics by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company's stock valued at $48,164,000 after acquiring an additional 49,367 shares in the last quarter. FMR LLC lifted its position in shares of Intellia Therapeutics by 5.0% during the 3rd quarter. FMR LLC now owns 2,339,522 shares of the company's stock valued at $48,077,000 after acquiring an additional 111,104 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock valued at $29,648,000 after acquiring an additional 98,865 shares during the period. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.